NO-naproxen AstraZeneca

IDrugs

Volumn 6, Issue 6, 2003, Pages 593-599

  Monck, Nat ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARP 900758; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NITRIC OXIDE NAPROXEN; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CHRONIC PAIN; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; REVIEW; STOMACH EROSION; STOMACH ULCER; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NAPROXEN; NITRIC OXIDE; NITRIC OXIDE DONORS; PAIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038693334     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 198694 Nic-Ox - A new nitric oxide company. SCRIP 1996 2102 15
2. 220948 NO-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects. Davies NM, Roseth AG, Appleyard CB, McKnight W, Del Soldato P, Calignano A, Cirino G, Wallace JL Aliment Pharmacol Ther 1997 511 1 69-79
3. 224210 Naproxen nitroxybutylester (HCT-3012): A nitrated derivative of naproxen devoid of gastrointestinal side effects. Cirino G, Calignano A, Del Soldato P, Robinson B, Wallace JL Int Congr Inflamm Res Assoc Abs W4 1996 Abs W4
4. 288550 Nitroflurbiprofen, a new nonsteroidal anti-inflammatory, ameliorates structural injury in the remnant kidney. Fujihara CK, Malheiros DM, Donato JL, Poli A, Du Nucci G, Zatz R Am J Physiol 274 3 PART 2 F573-F579
5. 300376 NicOx signs exclusive licence agreement for NO-NSAIDs with Astra. NicOx SA Press Release 1998 October 02
6. 326982 Effect of NO-naproxen on ischemia-reperfusion damage in the rat stomach: Comparison with naproxen and selective cyclooxygenase-2 inhibitors. Maricic N, Ehrlich KH, Peskar BM Gastroenterology 1999 May 16-19 Abs 1991
7. 332684 NO-naproxen modulates inflammation, pain and T cell responses in rat Freund's adjuvant arthritis. Cirino G, Calignano A, Iannaro A, Cicala C, Del Soldato P, Fiorucci S, Wallace JL Mediators Inflamm 1999 Suppl 1 S-27-4
8. 367350 NicOx receives milestone payment from AstraZeneca for initiation of phase I trial of HCT-3012. NicOx SA Press Release 2000 May 19
9. 396119 NicOx: Harnessing the power of nitric oxide. Technology Update: NiCox SA, London UK. Brown H Company Presentation 2001 January 16
10. 396746 NicOx's HCT-3012 advances into phase II human clinical trials: Company receives US$3 million milestone payment from AstraZeneca. NicOx SA Press Release 2001 January 24
11. 398869 Chemoenzymatic synthesis of antiinflammatory drugs in enantiomerically pure form. Basak A, Nag A, Bhattacharya G, Mandal S, Nag S Tetrahedron Asymmetry 2000 11 11 2403-2407
12. 402040 AstraZeneca - Annual Report & Form 20-F 2000. Annual Report AstraZeneca Plc 2001 Mary 15
13. 422343 Wishing to launch drugs in Japan within 6 months of the 1st launch overseas: Dr Kato of AstraZeneca. Pharma Jpn 2001 1757
14. 425318 NicOx - Unique expertise in nitric oxide drugs. BNP/Paribas 2001 August 29
15. 449793 Nitric oxide-releasing NSAIDs: A review of their current status. Fiorucci S, Antonelli E, Burgaud JL, Morelli A Drug SAF 2001 24 11 801-811
16. 449904 Nitric oxide-releasing NSAIDs inhibit interleukin-1β converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFα. Fiorucci S, Santucci L, Federici B, Antonelli E, Distrutti E, Morelli O, Renzo GD, Coata G, Cirino G, Del Soldato P, Morelli A Aliment Pharmacol Ther 1999 13 3 421-435
17. 454485 Bio 2002 - International Biotechnology Convention and Exhibition (Part V) - Overnight Report, Toronto, Canada. McGowran M IDDB Meeting Report 2002 June 9-12
18. 457376 World Congress of Pharmacology - XIVth Annual Meeting (Part II) - Overnight Report, San Francisco, CA, USA. Durrance A IDDB Meeting Report 2002 July 7-12
19. 457645 World Congress of Pharmacology - XIVth Annual Meeting (Part VI) - Overnight report, San Francisco, CA, USA. Durrance A IDDB Meeting Report 2002 July 7-12
20. 465449 NicOx signs exclusive agreement with AstraZeneca for the development of AZD3582 and other CINODs in Japan. NicOx SA Press Release 2002 September 30
21. 467771 NicOx granted US IND for phase II trials with NCX 4016 in cardiovascular diseases. NicOx SA Press Release 2000 October 24
22. 468856 EUFEPS 2002 - New safe medicines faster, Stockholm, Sweden. Ecker G IDDB Meeting Report 2002 October 20-23
23. 468970 NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Cicala C, Ianaro A, Fiorucci S, Calignano A, Bucci M, Gerli R, Santucci L, Wallace JL, Cirino G Br J Pharm 2000 130 6 1399-1405
24. 470881 Gastroenterology week - Tenth United European Annual Meeting, Geneva, Switzerland. IDDB Meeting Report 2002 October 19-23
25. 479412 NicOx requests full data file on AZD3582. NicOx SA Press Release 2003 February 20
26. 479180 AstraZeneca research update on AZD3582. AstraZeneca Plc Press Release 2003 February 18
27. 480468 NicOx reports year-end 2002 financial results. NicOx SA Press Release 2003 March 03
28. 481056 Company presentation - BIO CEO & Investor Conference, New York. Genome Therapeutics Corp Company Presentation 2003 February 26
29. 481066 Cyclooxygenase inhibition: Between the devil and the deep blue sea. Gut 2002 50 Suppl 3 iii25-iii30
30. 481068 Nitric oxide and gastroduodenal damage caused by NSAIDs. Recent findings and clinical implications. Dobrilla G Recenti Prog Med 2001 92 3 234-238
31. 481069 New issues about nitric oxide and its effects on the gastrointestinal tract. Martin MJ, Jimenez MD, Motilva V Curr Pharm Des 2001 7 10 881-908
32. 481084 A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Laine L, Harper S, Simon T, Bath R, Johnson J, Schwartz H, Stern S, Quan H, Bolognese J Gastroenterology 1999 117 4 776-783
33. 481099 Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J Arch of Intern Med 1996 156 21 2433-2439
34. 481103 Chiral mannitol as auxiliary in synthesis of optical active 2-arylpropanoic acids by 1,2-aryl enantioselective migrations. Wang B, Ma H-Z, Shi Q-Z Synth Commun 2002 32 11 1697-1702
35. 481108 Asymmetric dihydroxylation in an approach to the enantioselective synthesis of 2-arylpropanoic acid nonsteroidal antiinflammatory drugs. Griesbach RC, Hamon DP, Kennedy RJ Tetrahedron Asymmetry 1997 8 4 507-510
36. 481113 Stereoselective synthesis of (S)-(+)-naproxen catalyzed by carboxyl in a multicompartment electrolyzer. Creitch M, Chiari M, Carrea G J Biochem Biophys Methods 2001 48 3 247-256
37. 481118 A highly effective water-soluble polymer-supported catalyst for the two-phase asymmetric hydrogenation: Preparation and use of a PEG-bound BINAP ligand. Fan QH, Deng GJ, Chen XM, Xie WC, Jiang DZ, Liu DS, Chan AS J Mol Catal 2000 159 1 37-43
38. 481120 Highly effective chiral dipyridylphosphine ligands: Synthesis, structural determination, and applications in the Ru-catalyzed asymmetric hydrogenation reactions. Pai CC, Lin CW, Lin CC, Chen CC, Chan AS, Wong WT J Am Chem Soc 2000 122 46 11513-11514
39. 481184 Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Drozdowicz D, Kwiecien S, Pajdo R, Ptak A, Pawlik M, Digestive Liver Disease 2000 32 7 583-594
40. 481578 NicOx announces preliminary review of data from phase II study of AZD3582. NicOx SA Press Release 2003 March 11
41. 483085 NicOx informs: Positive phase II clinical data in acute pain presented on AZD3582. NicOx SA Press Release 2002 November 07
42. 487651 Role of tumor necrosis factor α release and leukocyte margination in indomethacin-induced gastric injury in rats. Santucci L, Fiorucci S, Di Matteo FM, Morelli A Gastroenterology 1995 108 2 393-401
43. 487653 Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: Role of tumour necrosis factor α. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A Gut 1994 35 7 909-915
44. 487654 Tumor necrosis factor mediation of NSAID-induced gastric damage: Role of leukocyte adherence. Appleyard CB, McCafferty DM, Tigley AW, Swain MG, Wallace KL Am J Physiol 1996 270 1 Pt 1 G42-G48
45. 487656 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK et al. N Engl J Med 2000 343 21 1520-1528
46. 487657 The coxibs, selective inhibitors of cyclooxygenase-2. Fitzgerald GA, Patrono C N Engl J Med 2001 345 6 433-442
47. 487661 COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Chandrasekhara NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL Proc Natl Acad Sci USA 2002 99 21 13926-13931
48. 487685 European Research Alert: Pharma daily perspective. Gregori F, Reeve J, Genis K BNP/Paribas 2003 April 02